论文部分内容阅读
Background: Low serum testosterone is associated with several cardiovas cular r isk factors including dyslipidaemia, adverse clotting profiles, obesity, and ins ulin resistance. Testosterone has been reported to improve symptoms of angina an d delay time to ischaemic threshold in unselected men with coronary disease. Obj ective: This randomised single blind placebo controlled crossover study compar ed testosterone replacement therapy (Sustanon 100) with placebo in 10 men with isc haemic heart disease and hypogonadism. Results: Baseline total testosterone and bioavailable testosterone were respectively 4.2 (0.5) nmol/l and 1.7 (0.4) nmol/ l. After a month of testosterone, delta value analysis between testosterone and placebo phase showed that mean (SD) trough testosterone concentrations increased significantly by 4.8 (6.6) nmol/l (total testosterone) (p=0.05) and 3.8 (4.5) n mol/l (bioavailable testosterone) (p=0.025), time to 1 mm ST segment depression assessed by Bruce protocol exercise treadmill testing increased by 74 (54) secon ds (p=0.002), and mood scores assessed with validated questionnaires all improve d. Compared with placebo, testosterone therapy was also associated with a signif icant reduction of total cholesterol and serum tumour necrosis factor αwith del ta values of -0.41 (0.54) mmol/l (p=0.04) and -1.8 (2.4) pg/ml (p=0.05) respec tively. Conclusion: Testosterone replacement therapy in hypogonadal men delays t ime to ischaemia, improves mood, and is associated with potentially beneficial r eductions of total cholesterol and serum tumour necrosis factor α.
Background: Low serum testosterone is associated with several cardiovas cular r isk factors including dyslipidaemia, adverse clotting profiles, obesity, and ins ulin resistance. Testosterone has been reported to improve symptoms of angina an d delay time to ischaemic threshold in unselected men with coronary disease Obj ective: This randomized single blind placebo controlled crossover study compar ed testosterone replacement therapy (Sustanon 100) with placebo in 10 men with ise haemic heart disease and hypogonadism. Results: Baseline total testosterone and bioavailable testosterone were respectively 4.2 (0.5) nmol / l and 1.7 (0.4) nmol / l After a month of testosterone, delta value analysis between testosterone and placebo phase showed that mean (SD) trough testosterone concentrations increased significantly by 4.8 (6.6) nmol / l total testosterone 0.05) and 3.8 (4.5) n mol / l (bioavailable testosterone) (p = 0.025), time to 1 mm ST segment depression assessed by Bruce protocol exerci se treadmill testing increased by 74 (54) secon ds (p = 0.002), and mood scores assessed with validated questionnaires all improve d. Compared with placebo, testosterone therapy was also associated with a signif icant reduction of total cholesterol and serum tumor necrosis factor αwith del ta values of -0.41 (0.54) mmol / l (p = 0.04) and -1.8 (2.4) pg / ml (p = 0.05) respecively. Conclusion: Testosterone replacement therapy in hypogonadal men delays t ime to ischaemia, improves mood, and is associated with potentially beneficial r eductions of total cholesterol and serum tumor necrosis factor α.